Novavax Inc said on Wednesday it has actually gone into a supply and license arrangement with the Serum Institute of India for the advancement and commercialization of its COVID-19 vaccine candidate.
The Indian drugmaker will have exclusive rights for the vaccine in India throughout the regard to the deal and non-exclusive rights throughout the “Pandemic Period” in all countries aside from those designated by the World Bank as upper-middle or high-income nations.
The deal was signed on July 30, according to an SEC filing by Novavax.
On Tuesday, Novavax reported that its experimental COVID-19 vaccine produced high levels of antibodies against the unique coronavirus in a little, early-stage clinical trial, which it could begin a big essential Phase III trial as quickly as late September.
Comments
Post a Comment